Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 16/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2802025 | 0.96 | PLA2G7 (0.61) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2804735 | 0.94 | PLA2G7 (0.67) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13988648 | 0.94 | PLA2G7 (0.65) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16864572 | 0.94 | PLA2G7 (0.57) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14024144 | 0.92 | CYP2C9 (0.55) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16705040 | 0.91 | PLA2G7 (0.55) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4761060 | 0.90 | PLA2G7 (0.65) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL13159705 | 0.90 | PLA2G7 (0.54) | PLA2G7CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2804665 | 0.90 | PLA2G7 (0.72) | PLA2G7CYP3A4CYP2D6 | |
| SCHEMBL2805366 | 0.89 | PLA2G7 (0.80) | PLA2G7CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | claimed |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-10-22 | — | — | US | claimed |
| EP-2155225-B1 | METHODS OF TREATMENT OF SKIN ULCERS | UNIV PENNSYLVANIA (US) | 2015-07-08 | — | — | EP | claimed |
| WO-2013185214-A1 | PLA2G7/LP-PLA2 AS BIOMARKER AND THERAPEUTIC TARGET IN THE PREVENTION AND TREATMENT OF CALCIFIC AORTIC VALVE DISEASE | UNIVERSITE LAVAL (CA) | 2013-12-19 | — | — | WO | claimed |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-09-23 | — | — | US | claimed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | claimed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | claimed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | claimed |
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | claimed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | claimed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | claimed |
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2977452-A2 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | ENPP2, PLA2G12A, PLA2G12B | PLA2G7 8/4885CYP3A4 2855/4885CYP2D6 2593/4885 |
| US-20080279846-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | PLA2G7 17/4885CYP3A4 4539/4885CYP2D6 4603/4885 |
| US-20150297597-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | PLA2G7 4/4885CYP3A4 4614/4885CYP2D6 4232/4885 |
| US-20100239565-A1 | METHODS OF TREATMENT OF SKIN ULCERS | PLA2G12A, PLA2G3, PLA2G4A | PLA2G7 4/4885CYP3A4 4614/4885CYP2D6 4232/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | PLA2G7 1/4885CYP3A4 2055/4885CYP2D6 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.